The net PAT of the pharma major stood at Rs 907.24 crore during the corresponding period of last fiscal.
According to the company, the total income for the quarter stood at Rs 2,965.71 crore -- down 10.14 per cent -- from Rs 3,300.22 crore reported during Q4 of 2015-16.
However, for the financial year ended 2017, the company's standalone net PAT rose by 11 per cent per cent to Rs 3,141.33 crore from Rs 2,830.87 crore during 2016-17. The total income for the year stood at Rs 12,841.62 crore from Rs 11,530.62 crore during the last financial year.
On a consolidated basis, the pharma major's net PAT (attributable to shareholders of the company) for the quarter under review fell by 49.16 per cent to Rs 380.21 crore from Rs 747.88 crore during Q4 2015-16.
On the other hand, the company's Q4 total income rose to Rs 4,298.64 crore from Rs 4,232.31 crore reported during the quarter ended March 31, 2016.
For the financial year ended 2017, the company's consolidated PAT (attributable to shareholders of the company) stood at Rs 2,557.46 crore and the total income stood at Rs 17,600.84 crore.
On the BSE, the scrip of the company fell by 1.71 per cent to Rs 1,227.65 per share.
(This story has not been edited by Social News XYZ staff and is auto-generated from a syndicated feed.)
About VDC
Doraiah Chowdary Vundavally is a Software engineer at VTech . He is the news editor of SocialNews.XYZ and Freelance writer-contributes Telugu and English Columns on Films, Politics, and Gossips. He is the primary contributor for South Cinema Section of SocialNews.XYZ. His mission is to help to develop SocialNews.XYZ into a News website that has no bias or judgement towards any.